Solid oral dosage form containing an enhancer

• US 8,053,429 B2
• Filed: 09/03/2009
• Issued: 11/08/2011
• Est. Priority Date: 02/22/1999
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Merrion Research III Limited
• Inventors: Cumming, Kenneth I., Ramtoola, Zebunnissa
• Primary Examiner(s): Lundgren; Jeffrey S.
• Assistant Examiner(s): Springer; Stephanie
• Application Number:
  US12/553,196
• Publication Number:
  US 20100028421A1
• Time in Patent Office: 796 Days
• Field of Search: None
• US Class Current: 514/183
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0002 Galenical forms characterised by the drug release technique; Application systems commanded by energy
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Claims

1. A solid oral dosage form which is effective in delivering a drug and an enhancer, each as defined below, to an intestine and which consists of a pharmaceutical composition consisting of:

(A) a therapeutically effective amount of a hydrophilic or macromolecular drug;

(B) one or more absorption enhancers, each of which;

(i) is a solid at room temperature;

(ii) is a salt of a medium chain fatty acid having a carbon length of from 8 to 14 carbon atoms; and

(iii) is present in the dosage form such that the ratio of the drug to the one or more absorption enhancers is 1;

100,000 to 10;

1;

(C) one or more excipients selected from the group consisting of rate-controlling polymeric materials, diluents, lubricants, disintegrants, plasticizers, anti-tack agents, opacifying agents, pigments, and flavorings; and

optionally, a controlled release coating;

wherein the solid oral dosage form is a tablet, a multiparticulate compressible to form a tablet, or a capsule containing a multiparticulate compressible to form a tablet.

2. The solid oral dosage form of claim 1, wherein the enhancer is a sodium salt of a medium chain fatty acid.

3. The solid oral dosage form of claim 2, wherein the enhancer is selected from the group consisting of sodium caprylate, sodium caprate and sodium laurate.

4. The solid oral dosage form of claim 2, wherein the absorption enhancer is sodium caprate.

5. The solid oral dosage form of claim 1, wherein the dosage form is a tablet.

6. The solid oral dosage form of claim 1, wherein the pharmaceutical composition has thereon an enteric coating.

7. The solid oral dosage form of claim 6, wherein the enteric-coated composition is a tablet.

8. The solid oral dosage form of claim 1, including a capsule which contains said pharmaceutical composition and which has thereon an enteric coating.

9. The solid oral dosage form of claim 1, wherein:

(A) the drug is selected from the group consisting of peptides, proteins, oligosaccharides, polysaccharides, and hormones; and

(B) the absorption enhancer is selected from the group consisting of sodium caprate, sodium caprylate, and sodium laurate.

10. The solid oral dosage form of claim 9, wherein the drug is an anticoagulant.

11. The solid oral dosage form of claim 10, wherein the anticoagulant is selected from the group consisting of heparin, low molecular weight heparin, heparinoids, hirudin, and analogues of the foregoing.

12. The solid oral dosage form of claim 10, wherein the anticoagulant is heparin.

13. The solid oral dosage form of claim 10, wherein the anticoagulant is low molecular weight heparin.

14. The solid oral dosage form of claim 1, wherein the drug is a bisphosphonate.

15. The solid oral dosage form of claim 14, wherein the bisphosphonate is alendronate.

16. The solid oral dosage form of claim 14, wherein the bisphosphonate is etidronate.

17. The solid oral dosage form of claim 15, wherein the absorption enhancer is sodium caprate and the ratio of the alendronate to the sodium caprate is 1:

1000 to 10;

1.

18. The solid oral dosage form of claim 1, wherein the drug is a peptide.

19. The solid oral dosage form of claim 1, wherein the drug is a protein.

20. The solid oral dosage form of claim 1, wherein the drug is an oligosaccharide.

21. The solid oral dosage form of claim 1, wherein the drug is a polysaccharide.

22. The solid oral dosage form of claim 1, wherein the drug is a hormone.

23. The solid oral dosage form of claim 5, wherein the tablet is a sustained-release tablet.

24. The solid oral dosage form of claim 23, wherein one of the excipients is a rate-controlling polymeric material.

25. The solid oral dosage form of claim 24, wherein the rate-controlling polymeric material is hydroxypropyl-methylcellulose.

26. The oral dosage form of claim 24, wherein the rate-controlling polymer comprises a polymer selected from the group consisting of poly(acrylic acid), polyacrylate, poly(methacrylic acid), polymethacrylate, and mixtures thereof.

27. The solid oral dosage form of claim 5, wherein the tablet is an instant-release tablet.

28. The solid oral dosage form of claim 6, wherein the enteric coating comprises a polymer selected from the group consisting of poly(acrylic acid), polyacrylate, poly(methacrylic acid), polymethacrylate, and mixtures thereof.

29. The solid oral dosage form of claim 1, wherein the pharmaceutical composition is in the form of a multiparticulate.

30. The solid oral dosage form according to claim 29, wherein the multiparticulate form comprises discrete particles, pellets, minitablets, or combinations thereof.

31. The solid oral dosage form according to claim 30 comprising a blend of two or more populations of particles, pellets or mini-tablets having different in vitro or in vivo release characteristics.

32. The solid oral dosage form according to claim 29, wherein the multiparticulate is encapsulated in hard or soft gelatin capsules.

33. The solid oral dosage form according to claim 32, wherein the capsule is coated with a rate-controlling polymer.

34. The solid oral dosage form of claim 29, wherein the multiparticulate is in the form of a tablet.

35. The solid oral dosage form according to claim 29, wherein the multiparticulate is incorporated into a sachet.

36. The solid oral dosage form according to claim 30, wherein the discrete particles or pellets are compressed into tablet form.

37. The solid oral dosage form according to claim 36, wherein the tablet form is coated with a rate controlling polymer material.

38. The solid oral dosage form according to claim 30, wherein the discrete particles or pellets are compressed into a multilayer tablet.

39. The solid oral dosage form according to claim 38 wherein the multilayer tablet is coated with a rate controlling material.

40. (withdrawn, currently amended) The solid oral dosage form of claim 1, wherein the pharmaceutical composition includes at least two absorption enhancers.

41. The solid oral dosage form of claim 1, wherein one of the excipients is a rate-controlling polymeric material.

42. The solid oral dosage form of claim 1, wherein one of the excipients is a diluent which is an inert filler selected from the group consisting of microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides and mixtures of any of the foregoing.

43. The solid oral dosage form of claim 42, wherein the inert filler is microcrystalline cellulose.

44. The solid oral dosage form of claim 42, wherein the inert filler is a lactose selected from the group consisting of lactose monohydrate and lactose anhydrous.

45. The solid oral dosage form of claim 42, wherein the inert filler is a saccharide selected from the group consisting of mannitol, starch, sorbitol, sucrose, and glucose.

46. The solid oral dosage form of claim 45, wherein the saccharide is sorbitol.

47. The solid oral dosage form of claim 1, wherein one of the excipients is a lubricant selected from the group consisting of colloidal silicon dioxide, talc, magnesium stearate, calcium stearate, and stearic acid.

48. The solid oral dosage form of claim 47, wherein the lubricant is stearic acid.

49. The solid oral dosage form of claim 1, wherein one of the excipients is a disintegrant selected from the group consisting of lightly crosslinked polyvinylpyrrolidone, corn starch, potato starch, maize starch and modified starches, croscarmellose sodium, crospovidone, and sodium starch glycolate.

50. The solid oral dosage form of claim 49, wherein the disintegrant is crospovidone.

51. The solid oral dosage form of claim 49, wherein the disintegrant is polyvinylpyrrolidone.

52. A process for the manufacture of a solid oral dosage form consisting of a pharmaceutical composition consisting of:

(A) a therapeutically effective amount of a hydrophilic or macromolecular drug;

(B) one or more absorption enhancers, each of which;

(i) is a solid at room temperature;

(ii) is a salt of a medium chain fatty acid having a carbon length of from 8 to 14 carbon atoms; and

(iii) is present in the dosage form such that the ratio of the drug to the one or more absorption enhancers is 1;

100,000 to 10;

1;

(C) one or more excipients selected from the group consisting of rate-controlling polymeric materials, diluents, lubricants, disintegrants, plasticizers, anti-tack agents, opacifying agents, pigments, and flavorings; and

optionally, a controlled release coating;

the process comprising the steps of;

a) blending a hydrophilic or macromolecular drug with one or more absorption enhancers, and optionally additional excipients, to form a blend;

wherein each of the absorption enhancers;

(i) is a solid at room temperature; and

(ii) is a salt of a medium chain fatty acid having a carbon length of from 8 to 14 carbon atoms in particulate form; and

b) forming a solid oral dosage form from the blend by i) direct compression of the blend to form the solid oral dosage form, or ii) granulating the blend to form a granulate for incorporation into the solid oral dosage form, or iii) spray drying the blend to form a multiparticulate for incorporation into the solid oral dosage form;

wherein the solid oral dosage form is a tablet, a multiparticulate compressible to form a tablet, or a capsule containing a multiparticulate compressible to form a tablet.

53. The process according to claim 52 wherein the drug and the enhancer are blended in a ratio of from 1:

100000 to 10;

1 (drug;

enhancer).